Ignite Creation Date:
2024-05-05 @ 11:21 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002012
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
Double-Blind Randomized Placebo-Controlled Study of Low Dose Oral Interferon Alfa-n3 Human Leukocyte Derived in ARC Patients
Sponsor:
Interferon Sciences
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
Double-Blind Randomized Placebo-Controlled Study of Low Dose Oral Interferon Alfa-n3 Human Leukocyte Derived in ARC Patients
Status:
COMPLETED
Status Verified Date:
1993-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To conduct a parallel-group double-blind randomized placebo-controlled study to evaluate the safety and efficacy of an orally administered low dose interferon alfa-n3 as an immunomodulator in the treatment of mild to moderate symptomatic HIV AIDS-related complex ARC patients
Detailed Description:
The study has been extended to offer 52 weeks of maintenance therapy after the 10 weeks of the placebo controlled period are concluded successfully
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 90-151ME | None | None | None |